Search Results - "Lokhnygina, Y"

109 Delayed Stress Delta N-Terminal Pro-B Type Natriuretic Peptide Is Significantly Higher With Myocardial Ischemia by Limkakeng, A.T, Lokhnygina, Y, Sandesara, H, Drake, W, Christenson, R, Newby, L.K

Get full text

111 Delayed Stress-Delta High Sensitivity Troponin Does Not Elevate With Myocardial Ischemia by Limkakeng, A.T, Lokhnygina, Y, Sandesara, H, Drake, W, Christenson, R, Newby, L.K

Get full text

903 The Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary Syndromes (TRILOGY ACS) Trial by Goodman, S.G, Roe, M.T, Armstrong, P.W, White, H.D, Fox, K.A, Prabhakaran, D, Brown, E, Lokhnygina, Y, Ohman, E

Get full text

Reduction in Total Cardiovascular Events With Ezetimibe/Simvastatin Post-Acute Coronary Syndrome: The IMPROVE-IT Trial by Murphy, Sabina A, Cannon, Christopher P, Blazing, Michael A, Giugliano, Robert P, White, Jennifer A, Lokhnygina, Yuliya, Reist, Craig, Im, KyungAh, Bohula, Erin A, Isaza, Daniel, Lopez-Sendon, Jose, Dellborg, Mikael, Kher, Uma, Tershakovec, Andrew M, Braunwald, Eugene

“…Intensive low-density lipoprotein cholesterol therapy with ezetimibe/simvastatin in IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International…”
Get full text

Higher risk of death and stroke in patients with persistent vs. paroxysmal atrial fibrillation: results from the ROCKET-AF Trial by Steinberg, Benjamin A, Hellkamp, Anne S, Lokhnygina, Yuliya, Patel, Manesh R, Breithardt, Günter, Hankey, Graeme J, Becker, Richard C, Singer, Daniel E, Halperin, Jonathan L, Hacke, Werner, Nessel, Christopher C, Berkowitz, Scott D, Mahaffey, Kenneth W, Fox, Keith A A, Califf, Robert M, Piccini, Jonathan P

“…Anticoagulation prophylaxis for stroke is recommended for at-risk patients with either persistent or paroxysmal atrial fibrillation (AF). We compared outcomes…”
Get full text

Management of major bleeding events in patients treated with rivaroxaban vs. warfarin: results from the ROCKET AF trial by Piccini, Jonathan P, Garg, Jyotsna, Patel, Manesh R, Lokhnygina, Yuliya, Goodman, Shaun G, Becker, Richard C, Berkowitz, Scott D, Breithardt, Günter, Hacke, Werner, Halperin, Jonathan L, Hankey, Graeme J, Nessel, Christopher C, Mahaffey, Kenneth W, Singer, Daniel E, Califf, Robert M, Fox, Keith A A

“…There are no data regarding management and outcomes of major bleeding events in patients treated with oral factor Xa inhibitors. Using data from ROCKET AF, we…”
Get full text

IL-6 inhibition with clazakizumab in patients receiving maintenance dialysis: a randomized phase 2b trial by Chertow, Glenn M., Chang, Anna Marie, Felker, G. Michael, Heise, Mark, Velkoska, Elena, Fellström, Bengt, Charytan, David M., Clementi, Regina, Gibson, C. Michael, Goodman, Shaun G., Jardine, Meg, Levin, Adeera, Lokhnygina, Yuliya, Mears, Jenny, Mehran, Roxana, Stenvinkel, Peter, Wang, Angela Yee-Moon, Wheeler, David C., Zoccali, Carmine, Ridker, Paul M., Mahaffey, Kenneth W., Tricoci, Pierluigi, Wolf, Myles

“…Inflammation mediated by interleukin-6 (IL-6) is strongly associated with cardiovascular risk. Here we evaluated clazakizumab, a monoclonal antibody targeting…”
Get full text

Safety of a peanut oral immunotherapy protocol in children with peanut allergy by Hofmann, Alison M., MD, Scurlock, Amy M., MD, Jones, Stacie M., MD, Palmer, Kricia P., MD, Lokhnygina, Yuliya, PhD, Steele, Pamela H., CPNP, Kamilaris, Janet, RN, Burks, A. Wesley, MD

“…Background Oral immunotherapy (OIT) offers a promising therapeutic option for peanut allergy. Given that during OIT an allergic patient ingests an allergen…”
Get full text

Applying novel methods to assess clinical outcomes: insights from the TRILOGY ACS trial by Bakal, Jeffrey A, Roe, Matthew T, Ohman, E Magnus, Goodman, Shaun G, Fox, Keith A A, Zheng, Yinggan, Westerhout, Cynthia M, Hochman, Judith S, Lokhnygina, Yuliya, Brown, Eileen B, Armstrong, Paul W

“…Several methods provide new insights into understanding clinical trial composite endpoints, using both conventional and novel methods. The TRILOGY ACS trial is…”
Get full text

Evaluation of Selvester QRS score for use in presence of conduction abnormalities in a broad population by Wieslander, Björn, MD, Nijveldt, Robin, MD, PhD, Klem, Igor, MD, Lokhnygina, Yuliya, PhD, Pura, John, MPH, Wagner, Galen S., MD, Ugander, Martin, MD, PhD, Atwater, Brett D., MD

“…Background The Selvester QRS score is an electrocardiographic tool designed to quantify myocardial scar. It was updated in 2009 to expand its usefulness in…”
Get full text

Reduction in recurrent ischemic events with vorapaxar: results from TRACER by White, H. D., Huang, Z., Tricoci, P., Van De Werf, F., Wallentin, L., Lokhnygina, Y., Moliterno, D., Aylward, P. E., Mahaffey, K., Armstrong, P. W.

Get full text

Discussion of the "Executive Summary of the PhRMA Working Group on Adaptive Designs in Clinical Drug Development" by Lokhnygina, Yuliya

Get full text

Progression of glucose‐lowering diabetes therapy in TECOS by Bethel, M. Angelyn, Engel, Samuel S., Stevens, Susanna R., Lokhnygina, Yuliya, Ding, Jie, Josse, Robert G., Alvarsson, Michael, Hramiak, Irene, Green, Jennifer B., Peterson, Eric D., Holman, Rury R.

“…Summary Aims TECOS was a randomized, double‐blind, placebo‐controlled trial assessing the impact of sitagliptin vs. placebo on cardiovascular outcomes when…”
Get full text

Racial/Ethnic Differences in the Rates and Correlates of HIV Risk Behaviors among Drug Abusers by Brooks, Audrey J., Lokhnygina, Yuliya, Meade, Christina S., Potter, Jennifer Sharpe, Calsyn, Donald A., Greenfield, Shelly F.

“…Background HIV infection disproportionately impacts minorities; yet research on racial/ethnic differences in the prevalence and correlates of HIV risk…”
Get full text

Timing of death and myocardial infarction in patients with non-ST elevation acute coronary syndromes: insights from randomized clinical trials by Mehta, Rajendra H, Greenbaum, Adam B, Lokhnygina, Yuliya, Newby, L Kristin, Van De Werf, Frans, Armstrong, Paul W, Pieper, Karen S, Califf, Robert M, Granger, Christopher B, Harrington, Robert A

“…Adverse events occur following non-ST elevation acute coronary syndromes (NSTE ACS). However, the timing of these events in relation to index event is less…”
Get more information